PBAC's latest decision on Desmopressin acetate: Recommended (2025). Considered for Treatment of cranial diabetes insipidus and primary nocturnal enuresis.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Patients with cranial diabetes insipidus or primary nocturnal enuresis (≥6 years of age for enuresis; those refractory to enuresis alarm or in whom alarm is contraindicated).
Therapy area
Endocrinology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Minirin nasal spray
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. PBAC recommended cost-minimisation to Minirin nasal spray on a per actuation basis.